Core Thesis Behind Lifecore Biomedical (LFCR): Monetizing Excess Capacity

Greenhaven Road Capital, an investment management firm, revealed in their Q2 2026 investor letter that Lifecore Biomedical, Inc. (NASDAQ:LFCR) is a company they are keeping a close eye on. The main premise of their thesis is that the company can monetize its excess manufacturing capacity. Over the past nine months, Lifecore Biomedical, Inc. has secured seven new customers and, despite the lengthy FDA approval process, these contracts are expected to be highly valuable due to their stickiness.

The company's recent SEC filing shows that they are actively exploring various strategic options, including potential sales. With insiders holding more than 30% of the company, a sale could potentially occur at a significant premium to the current share price. The company's growth is anticipated to return in 2027 and accelerate in 2028, although it remains unclear if Lifecore Biomedical, Inc. will continue to be publicly traded.